SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are recommended to lower risk of HF hospitalization in patients with diabetes and have been shown to reduce SBP in type 2 diabetic patients by 3–4 mmHg, similar in size to the reduction obtained with a low dose of a thiazide diuretic.14